Author: Marshall Beck

AllerGen begins NCE wind-down

After receiving the full 14 years of national Networks of Centres of Excellence (NCE) funding, today—April 1, 2019—AllerGen begins a two-year wind-down of its NCE mandate. Dr. Judah Denburg, who has led the Network since its planning stages in 2002,

Michelle Harkness Mentorship Awards celebrate & promote mentoring excellence

On the evening of January 29, 2019, at the Gala event of AllerGen’s final Research Conference, eight exceptional members of the AllerGen network were recognized for their excellence as mentors, and four others were awarded grants to support the development

AllerGen investigators lead two platforms of new pan-Canadian microbiome research core

The CIHR is funding a new, national microbiome research core, and two of its five platforms are headed by AllerGen investigators. The University of Calgary-based initiative, The Integrated Microbiome Platforms for Advancing Causation Testing and Translation, or IMPACTT, brings together

AllerGen’s final research conference… and beyond

Marking the culmination of 14 years of research, AllerGen held its ninth and final Research Conference from January 27-30, 2019, in Toronto, ON. Over 220 delegates participated. Nearly half were AllerGen trainees, some of whom have been involved in the

Infant sleep duration associated with mother’s level of education, prenatal depression and method of delivery

New research from AllerGen’s CHILD Cohort Study has found that babies sleep less at three months of age if their mothers do not have a university degree, experienced depression during pregnancy or had an emergency cesarean-section delivery. “Sleep affects a

Allergic reactions frequent in children undergoing milk oral immunotherapy

Oral immunotherapy (OIT) is a relatively new approach to treating food allergies that exposes allergic patients to gradually increased doses of an allergenic food to desensitize their immune systems. While OIT can be safely used to treat the majority of

Dr. Moshe Ben-Shoshan funded to study children’s allergies to antibiotics

AllerGen investigator Dr. Moshe Ben-Shoshan (Montreal Children’s Hospital) has been awarded a four-year, $336,000 CIHR Project Grant to explore adverse reactions to antibiotics among children. His project aims to determine how often these adverse reactions—typically seen in the form of

AllerGen salutes Board Member Don Green

It is with deep sorrow that we announce the passing of an AllerGen supporter and friend, Mr. Donald Green, on Monday, February 18, 2019. Mr. Green was a member of AllerGen’s Board of Directors and Chair of its Budget and

Breastmilk microbiome linked to method of feeding

New research from the CHILD Cohort Study sheds some light on the importance of the infant’s mouth as a source of breastmilk bacteria. The idea that breastmilk has a microbiome—a community of bacteria living within it—is relatively new and has

HQP video describes public health surveillance of asthma in Ontario

In a knowledge translation video prepared for AllerGen’s HQP Video Competition, AllerGen trainees Laura Feldman and Natasha Gray, in collaboration with their colleague Dresden Glockler-Lauf, provide an introduction to public health surveillance and describe how it is being used by

CHILD microbiome paper is CMAJ‘s top article for 2018 media coverage

A study led by AllerGen investigator Dr. Anita Kozyrskyj and published in the Canadian Medical Association Journal (CMAJ) in September 2018, is the journal’s top article for 2018 in terms of media coverage. The study used data from CHILD Study

Suboptimal, inconsistent treatment for anaphylaxis when the cause is unknown

A new C-CARE study is shedding light on “anaphylaxis due to an unknown trigger” (AUT), a medical condition about which surprisingly little is known. The study, published in The Journal of Allergy and Clinical Immunology: In Practice, followed nearly 4,000

Top